Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 211

1.

ERK1/2 signaling regulates the immune microenvironment and macrophage recruitment in glioblastoma.

Lailler C, Louandre C, Morisse MC, Lhossein T, Godin C, Lottin M, Constans JM, Chauffert B, Galmiche A, Saidak Z.

Biosci Rep. 2019 Sep 13;39(9). pii: BSR20191433. doi: 10.1042/BSR20191433. Print 2019 Sep 30.

2.

Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study.

Morisse MC, Etienne-Selloum N, Bello-Roufai D, Blonski M, Taillandier L, Lorgis V, Noël G, Ahle G, Durán-Peña A, Boone M, Chauffert B.

J Neurooncol. 2019 Sep;144(2):419-426. doi: 10.1007/s11060-019-03245-5. Epub 2019 Jul 19.

PMID:
31325146
3.

Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy.

Mazard T, Assenat E, Dupuy M, Mollevi C, René A, Adenis A, Chauffert B, Boucher E, Francois E, Pierga JY, Ducreux M, Ychou M, Gallix B.

Dig Liver Dis. 2019 Aug;51(8):1185-1191. doi: 10.1016/j.dld.2019.03.028. Epub 2019 May 10.

PMID:
31085108
4.

Combining genomic analyses with tumour-derived slice cultures for the characterization of an EGFR-activating kinase mutation in a case of glioblastoma.

Loriguet L, Morisse MC, Dremaux J, Collet L, Attencourt C, Coutte A, Boone M, Sevestre H, Galmiche A, Gubler B, Chauffert B, Trudel S.

BMC Cancer. 2018 Oct 11;18(1):964. doi: 10.1186/s12885-018-4873-9.

5.

A pan-cancer study of the transcriptional regulation of uricogenesis in human tumours: pathological and pharmacological correlates.

Saidak Z, Louandre C, Dahmani S, Sauzay C, Guedda S, Chauffert B, Chatelain D, Ceballos-Picot I, Galmiche A.

Biosci Rep. 2018 Sep 19;38(5). pii: BSR20171716. doi: 10.1042/BSR20171716. Print 2018 Oct 31.

6.

Squamous Cell Carcinoma Antigen-encoding Genes SERPINB3/B4 as Potentially Useful Markers for the Stratification of HNSCC Tumours.

Saidak Z, Morisse MC, Chatelain D, Sauzay C, Houessinon A, Guilain N, Soyez M, Chauffert B, Dakpé S, Galmiche A.

Anticancer Res. 2018 Mar;38(3):1343-1352.

PMID:
29491058
7.

Impact of homogeneous pathologic response to preoperative chemotherapy in patients with multiple colorectal liver metastases.

Sabbagh C, Chatelain D, Attencourt C, Joly JP, Chauffert B, Cosse C, Regimbeau JM.

World J Gastroenterol. 2017 Dec 7;23(45):8027-8034. doi: 10.3748/wjg.v23.i45.8027.

8.

Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism.

Jannin A, Hennart B, Adenis A, Chauffert B, Penel N.

Case Rep Oncol Med. 2017;2017:2683478. doi: 10.1155/2017/2683478. Epub 2017 Sep 26.

9.

Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment.

Darmon I, Morisse MC, Coutte A, Blonski M, Le Rhun E, Taillandier L, Roufai DB, Desenclos C, Trudel S, Faivre JC, Blanchard N, Chauffert B, Boone M.

J Cancer. 2017 May 12;8(8):1417-1424. doi: 10.7150/jca.18339. eCollection 2017.

10.

Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).

Lebellec L, Chauffert B, Blay JY, Le Cesne A, Chevreau C, Bompas E, Bertucci F, Cupissol D, Fabbro M, Saada-Bouzid E, Duffaud F, Feuvret L, Bonneville-Levard A, Bay JO, Vauleon E, Vinceneux A, Noel G, Penel N, Mir O.

Eur J Cancer. 2017 Jul;79:119-128. doi: 10.1016/j.ejca.2017.03.037. Epub 2017 May 4.

PMID:
28478340
11.

Could Patients Older than 75 Years Benefit from a Systematic Breast Cancer Screening Program?

Ilenko A, Sergent F, Mercuzot A, Zitoun M, Chauffert B, Foulon A, Gondry J, Chevreau J.

Anticancer Res. 2017 Feb;37(2):903-907.

PMID:
28179350
12.

Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma.

Sauzay C, Petit A, Bourgeois AM, Barbare JC, Chauffert B, Galmiche A, Houessinon A.

Clin Chim Acta. 2016 Dec 1;463:39-44. doi: 10.1016/j.cca.2016.10.006. Epub 2016 Oct 11. Review.

PMID:
27732875
13.

Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab.

Dupont B, Mariotte D, Dugué AE, Clarisse B, Grellard JM, Babin E, Chauffert B, Dakpé S, Moldovan C, Bouhier-Leporrier K, Reimund JM, Di Fiore F, Zanetta S, Mailliez A, Do P, Peytier A, Galais MP, Florescu C, Schott R, Le Mauff B, Gervais R.

Br J Clin Pharmacol. 2017 Mar;83(3):623-631. doi: 10.1111/bcp.13140. Epub 2016 Oct 24.

14.

[The use of the G8 score for the patient of more than 75years old in digestive surgery for cancer].

Sabbagh C, Cosse C, Fournier R, Carola E, Chauffert B, Dumesnil R, Regimbeau JM.

Bull Cancer. 2016 Oct;103(10):896-897. doi: 10.1016/j.bulcan.2016.08.004. Epub 2016 Oct 3. French. No abstract available.

PMID:
27712831
15.

[Lung cancer screening with low-dose thoracic CT-scan in the Somme area].

Leleu O, Auquier M, Carre O, Chauffert B, Dubreuil A, Petigny V, Trancart B, Berna P, Jounieaux V.

Rev Mal Respir. 2017 Mar;34(3):262-267. doi: 10.1016/j.rmr.2016.08.003. Epub 2016 Oct 12. French.

PMID:
27743826
16.

Intra-Arterial Delivery of Idarubicin in Two Patients with Glioblastoma.

Chehimi M, Boone M, Chivot C, Deramond H, Constans JM, Ly MC, Chauffert B.

Case Rep Oncol. 2016 Aug 30;9(2):499-505. eCollection 2016 May-Aug.

17.

Thrombotic Microangiopathy Revealing Bone Metastases from an Ethmoid Sinus Carcinoma.

Morisse MC, Kontar L, Bihan C, Boone M, Lachaier E, Titeca-Beauport D, Maizel J, Chauffert B.

Case Rep Oncol. 2016 Aug 17;9(2):470-473. eCollection 2016 May-Aug.

18.

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma.

Bertaut A, Truntzer C, Madkouri R, Kaderbhai CG, Derangère V, Vincent J, Chauffert B, Aubriot-Lorton MH, Farah W, Mourier KL, Boidot R, Ghiringhelli F.

Oncotarget. 2016 Oct 25;7(43):70948-70958. doi: 10.18632/oncotarget.10898.

19.

Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma.

Paquette B, Vernerey D, Chauffert B, Dabakuyo S, Feuvret L, Taillandier L, Frappaz D, Taillia H, Schott R, Ducray F, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O, Anota A, Bonnetain F.

Cancer Med. 2016 Aug;5(8):1753-64. doi: 10.1002/cam4.734. Epub 2016 Jun 1.

20.

Prevalence and profile of cognitive impairment in adult glioma: a sensitivity analysis.

Boone M, Roussel M, Chauffert B, Le Gars D, Godefroy O.

J Neurooncol. 2016 Aug;129(1):123-30. doi: 10.1007/s11060-016-2152-7. Epub 2016 May 30.

PMID:
27241133
21.

Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.

Houessinon A, François C, Sauzay C, Louandre C, Mongelard G, Godin C, Bodeau S, Takahashi S, Saidak Z, Gutierrez L, Régimbeau JM, Barget N, Barbare JC, Ganne N, Chauffert B, Coriat R, Galmiche A.

Mol Cancer. 2016 May 16;15(1):38. doi: 10.1186/s12943-016-0526-2.

22.

Probing Tumour Proteostasis and the UPR with Serum Markers.

Galmiche A, Sauzay C, Houessinon A, Chauffert B, Pluquet O.

Trends Cancer. 2016 May;2(5):219-221. doi: 10.1016/j.trecan.2016.04.004. Epub 2016 Apr 28.

PMID:
28741509
23.

Short-term culture of tumour slices reveals the heterogeneous sensitivity of human head and neck squamous cell carcinoma to targeted therapies.

Donnadieu J, Lachaier E, Peria M, Saidak Z, Dakpe S, Ikoli JF, Chauffert B, Page C, Galmiche A.

BMC Cancer. 2016 Apr 16;16:273. doi: 10.1186/s12885-016-2318-x.

24.

[Innovative anticancer agents reserved to hospital use and not involved in the hospital budget: Creation and evolution].

Freyer G, Marty M; membres du groupe de travail, Blay JY, Chauffert B, Ganem G, Lotz JP, Marchal F, Medioni J, Ray-Coquard I.

Bull Cancer. 2016 Apr;103(4):315-7. doi: 10.1016/j.bulcan.2016.02.013. Epub 2016 Mar 29. French. No abstract available.

PMID:
27036539
25.

[Systemic therapies administration for adult patients in neuro-oncology: The standards of the Association of the neuro-oncologists of French expression (ANOCEF)].

Simon N, Vasseur M, Chauffert B, Taillandier L, Le Rhun E.

Bull Cancer. 2016 Apr;103(4):400-1. doi: 10.1016/j.bulcan.2016.01.011. Epub 2016 Feb 10. French. No abstract available.

PMID:
26874975
26.

Personalization of the medical treatment of solid tumours using patient-derived tumour explants (Review).

Louandre C, Donnadieu J, Lachaier E, Page C, Chauffert B, Galmiche A.

Int J Oncol. 2016 Mar;48(3):895-9. doi: 10.3892/ijo.2016.3345. Epub 2016 Jan 18. Review.

PMID:
26783093
27.

Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib.

Houessinon A, Gicquel A, Bochereau F, Louandre C, Nyga R, Godin C, Degonville J, Fournier E, Saidak Z, Drullion C, Barbare JC, Chauffert B, François C, Pluquet O, Galmiche A.

Cancer Lett. 2016 Jan 28;370(2):242-9. doi: 10.1016/j.canlet.2015.10.032. Epub 2015 Nov 3.

PMID:
26546044
28.

Oncological strategies for middle and low rectal cancer with synchronous liver metastases.

Sabbagh C, Cosse C, Ravololoniaina T, Chauffert B, Joly JP, Mauvais F, Regimbeau JM.

Int J Surg. 2015 Nov;23(Pt A):186-93. doi: 10.1016/j.ijsu.2015.08.034. Epub 2015 Aug 24.

29.

Management of colon cancer in patients with cirrhosis: A review.

Sabbagh C, Cosse C, Chauffert B, Nguyen-Khac E, Joly JP, Yzet T, Regimbeau JM.

Surg Oncol. 2015 Sep;24(3):187-93. doi: 10.1016/j.suronc.2015.06.010. Epub 2015 Jun 12. Review.

PMID:
26093942
30.

Evaluation of individual sensitivity of head and neck squamous cell carcinoma to cetuximab by short-term culture of tumor slices.

Peria M, Donnadieu J, Racz C, Ikoli JF, Galmiche A, Chauffert B, Page C.

Head Neck. 2016 Apr;38 Suppl 1:E911-5. doi: 10.1002/hed.24126. Epub 2015 Aug 13.

PMID:
25994489
31.

Sustained response of a clivus chordoma to erlotinib after imatinib failure.

Houessinon A, Boone M, Constans JM, Toussaint P, Chauffert B.

Case Rep Oncol. 2015 Jan 22;8(1):25-9. doi: 10.1159/000371843. eCollection 2015 Jan-Apr.

32.

Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib.

Godin C, Louandre C, Bodeau S, Diouf M, Saidak Z, Conte MA, Chauffert B, Barbare JC, Barget N, Trinchet JC, Ganne N, Galmiche A.

Anticancer Res. 2015 Mar;35(3):1803-8.

PMID:
25750346
33.

Molecular targeted therapies in advanced or metastatic chordoma patients: facts and hypotheses.

Lebellec L, Aubert S, Zaïri F, Ryckewaert T, Chauffert B, Penel N.

Crit Rev Oncol Hematol. 2015 Jul;95(1):125-31. doi: 10.1016/j.critrevonc.2015.01.010. Epub 2015 Jan 30. Review.

PMID:
25682222
34.

Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.

Chougnet CN, Borget I, Leboulleux S, de la Fouchardiere C, Bonichon F, Criniere L, Niccoli P, Bardet S, Schneegans O, Zanetta S, Schvartz C, Drui D, Chauffert B, Rohmer V, Schlumberger M.

Thyroid. 2015 Apr;25(4):386-91. doi: 10.1089/thy.2014.0361. Epub 2015 Feb 18.

PMID:
25627619
35.

The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.

Louandre C, Marcq I, Bouhlal H, Lachaier E, Godin C, Saidak Z, François C, Chatelain D, Debuysscher V, Barbare JC, Chauffert B, Galmiche A.

Cancer Lett. 2015 Jan 28;356(2 Pt B):971-7. doi: 10.1016/j.canlet.2014.11.014. Epub 2014 Nov 12.

PMID:
25444922
36.

The role of reactive oxygen species and subsequent DNA-damage response in the emergence of resistance towards resveratrol in colon cancer models.

Colin DJ, Limagne E, Ragot K, Lizard G, Ghiringhelli F, Solary É, Chauffert B, Latruffe N, Delmas D.

Cell Death Dis. 2014 Nov 20;5:e1533. doi: 10.1038/cddis.2014.486.

37.

Two cases of fatal encephalopathy related to Ifosfamide: an adverse role of aprepitant?

Séjourné A, Noal S, Boone M, Bihan C, Sassier M, Andrejak M, Chauffert B.

Case Rep Oncol. 2014 Sep 25;7(3):669-72. doi: 10.1159/000368184. eCollection 2014 Sep.

38.

Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors.

Lachaier E, Louandre C, Godin C, Saidak Z, Baert M, Diouf M, Chauffert B, Galmiche A.

Anticancer Res. 2014 Nov;34(11):6417-22.

PMID:
25368241
39.

Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study.

Phelip JM, Vendrely V, Rostain F, Subtil F, Jouve JL, Gasmi M, Michel P, Le Malicot K, Smith D, Seitz JF, Fauchart JP, Martin P, Bennouna J, Morin T, Bonnet I, Maingon P, Lepage C, Chauffert B.

Eur J Cancer. 2014 Nov;50(17):2975-82. doi: 10.1016/j.ejca.2014.08.013. Epub 2014 Sep 17.

PMID:
25241229
40.

[Ferroptosis, a new form of cell death relevant to the medical treatment of cancer].

Lachaier E, Louandre C, Ezzoukhry Z, Godin C, Mazière JC, Chauffert B, Galmiche A.

Med Sci (Paris). 2014 Aug-Sep;30(8-9):779-83. doi: 10.1051/medsci/20143008016. Epub 2014 Sep 1. Review. French.

41.

High pressure does not counterbalance the advantages of open techniques over closed techniques during heated intraperitoneal chemotherapy with oxaliplatin.

Facy O, Combier C, Poussier M, Magnin G, Ladoire S, Ghiringhelli F, Chauffert B, Rat P, Ortega-Deballon P.

Surgery. 2015 Jan;157(1):72-8. doi: 10.1016/j.surg.2014.06.006. Epub 2014 Jul 12.

PMID:
25027716
42.

Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial.

Boulin M, Hillon P, Cercueil JP, Bonnetain F, Dabakuyo S, Minello A, Jouve JL, Lepage C, Bardou M, Wendremaire M, Guerard P, Denys A, Grandvuillemin A, Chauffert B, Bedenne L, Guiu B.

Aliment Pharmacol Ther. 2014 Jun;39(11):1301-13. doi: 10.1111/apt.12746. Epub 2014 Apr 16.

43.

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.

Chauffert B, Feuvret L, Bonnetain F, Taillandier L, Frappaz D, Taillia H, Schott R, Honnorat J, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O.

Ann Oncol. 2014 Jul;25(7):1442-7. doi: 10.1093/annonc/mdu148. Epub 2014 Apr 9.

PMID:
24723487
44.

New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma.

Galmiche A, Chauffert B, Barbare JC.

Cancer Lett. 2014 May 1;346(2):159-62. doi: 10.1016/j.canlet.2013.12.028. Epub 2013 Dec 28. Review.

PMID:
24380851
45.

[A peripartum lumbosciatica revealing an Ewing sarcoma of the pelvis].

Séjourné A, Paupière S, Bonnaire B, Ikoli JF, Chauffert B, Goëb V.

J Gynecol Obstet Biol Reprod (Paris). 2014 Jun;43(6):474-7. doi: 10.1016/j.jgyn.2013.11.002. Epub 2013 Dec 6. French. No abstract available.

46.

About the Rationale for Heating Oxaliplatin During HIPEC.

Ortega-Deballon P, Facy O, Rat P, Chauffert B.

Ann Surg. 2016 Apr;263(4):e60. doi: 10.1097/SLA.0000000000000347. No abstract available.

PMID:
24169194
47.

cis-Dichloroplatinum(II) complexes tethered to dibenzo[c,h][1,6]naphthyridin-6-ones: synthesis and cytotoxicity in human cancer cell lines in vitro.

Desbois N, Pertuit D, Moretto J, Cachia C, Chauffert B, Bouyer F.

Eur J Med Chem. 2013 Nov;69:719-27. doi: 10.1016/j.ejmech.2013.09.037. Epub 2013 Sep 26.

PMID:
24095763
48.

Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma.

Darlix A, Baumann C, Lorgis V, Ghiringhelli F, Blonski M, Chauffert B, Zouaoui S, Pinelli C, Rech F, Beauchesne P, Taillandier L.

Anticancer Res. 2013 Aug;33(8):3467-74.

PMID:
23898121
49.

Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma.

Wiazzane N, Chauffert B, Ghiringhelli F.

Clin Res Hepatol Gastroenterol. 2013 Dec;37(6):614-8. doi: 10.1016/j.clinre.2013.03.003. Epub 2013 May 25.

PMID:
23711827
50.

Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments.

Godin C, Dupont S, Ezzoukhry Z, Louandre C, Chatelain D, Henaut L, Sabbagh C, Regimbeau JM, Maziere JC, Barbare JC, Chauffert B, Galmiche A.

Anticancer Res. 2013 Apr;33(4):1415-20.

PMID:
23564781

Supplemental Content

Loading ...
Support Center